Not medical advice: Educational content only. Author is not a doctor. Consult a licensed healthcare professional.
Educational summary of scientific literature on ivermectin in oncology research
Important: Ivermectin is NOT approved as a cancer treatment. It is FDA-approved only as an antiparasitic medication. This content is educational only.
Ivermectin is an FDA-approved antiparasitic medication with decades of established safety data for its approved indications. It was developed in the 1970s and has been widely used globally.
The discovery of ivermectin led to a Nobel Prize in Physiology or Medicine in 2015 for its impact on treating parasitic diseases.
Laboratory observations suggest Ivermectin may interact with cancer-relevant pathways including:
No. Ivermectin is approved as an antiparasitic drug. While preclinical research suggests potential anticancer effects and some early oncology trials have begun, ivermectin is not approved as a cancer therapy and its anticancer effectiveness in humans remains unproven.
DO NOT combine Ivermectin and Fenbendazole without medical supervision. Both compounds are metabolized by the liver and combining them may increase the risk of hepatotoxicity (liver damage). Regular liver function monitoring is essential if using either compound.